Literature DB >> 18034184

Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations.

James D Fackenthal1, Olufunmilayo I Olopade.   

Abstract

Germline mutations in the BRCA1 or BRCA2 tumour-suppressor genes are strong predictors of breast and/or ovarian cancer development. The contribution of these mutations to breast cancer risk within any specific population is a function of both their prevalence and their penetrance. Mutation prevalence varies among ethnic groups and may be influenced by founder mutations. Penetrance can be influenced by mutation-specific phenotypes and the potential modifying effects of the patient's own genetic and environmental background. Although estimates of both mutation prevalence and mutation penetrance rates are inconsistent and occasionally controversial, understanding them is crucial for providing accurate risk information to each patient.

Entities:  

Mesh:

Year:  2007        PMID: 18034184     DOI: 10.1038/nrc2054

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  171 in total

1.  CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice.

Authors:  Eun-Hee Kim; Chuxia Deng; Michael B Sporn; Darlene B Royce; Renee Risingsong; Charlotte R Williams; Karen T Liby
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-20

2.  Novel germline PALB2 truncating mutations in African American breast cancer patients.

Authors:  Yonglan Zheng; Jing Zhang; Qun Niu; Dezheng Huo; Olufunmilayo I Olopade
Journal:  Cancer       Date:  2011-08-26       Impact factor: 6.860

3.  Breast cancer risk from different mammography screening practices.

Authors:  Harmen Bijwaard; Alina Brenner; Fieke Dekkers; Teun van Dillen; Charles E Land; John D Boice
Journal:  Radiat Res       Date:  2010-09       Impact factor: 2.841

Review 4.  Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes.

Authors:  Sasagu Kurozumi; Yuri Yamaguchi; Masafumi Kurosumi; Miki Ohira; Hiroshi Matsumoto; Jun Horiguchi
Journal:  J Hum Genet       Date:  2016-07-21       Impact factor: 3.172

Review 5.  Pathway perturbations in signaling networks: Linking genotype to phenotype.

Authors:  Yongsheng Li; Daniel J McGrail; Natasha Latysheva; Song Yi; M Madan Babu; Nidhi Sahni
Journal:  Semin Cell Dev Biol       Date:  2018-05-10       Impact factor: 7.727

6.  BRCA1/2 mutations, fertility and the grandmother effect.

Authors:  Jack da Silva
Journal:  Proc Biol Sci       Date:  2012-05-09       Impact factor: 5.349

7.  Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody.

Authors:  Hong Song; Mohammad Hedayati; Robert F Hobbs; Chunbo Shao; Frank Bruchertseifer; Alfred Morgenstern; Theodore L Deweese; George Sgouros
Journal:  Mol Cancer Ther       Date:  2013-07-19       Impact factor: 6.261

8.  Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.

Authors:  Priyanka Sharma; Jennifer R Klemp; Bruce F Kimler; Jonathan D Mahnken; Larry J Geier; Qamar J Khan; Manana Elia; Carol S Connor; Marilee K McGinness; Joshua M W Mammen; Jamie L Wagner; Claire Ward; Lori Ranallo; Catherine J Knight; Shane R Stecklein; Roy A Jensen; Carol J Fabian; Andrew K Godwin
Journal:  Breast Cancer Res Treat       Date:  2014-05-07       Impact factor: 4.872

Review 9.  FANCJ helicase operates in the Fanconi Anemia DNA repair pathway and the response to replicational stress.

Authors:  Yuliang Wu; Robert M Brosh
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

Review 10.  Impaired DNA damage response--an Achilles' heel sensitizing cancer to chemotherapy and radiotherapy.

Authors:  Zbigniew Darzynkiewicz; Frank Traganos; Donald Wlodkowic
Journal:  Eur J Pharmacol       Date:  2009-10-18       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.